Tango Therapeutics is a clinical-stage biotechnology company whose investment case rests almost entirely on the progress of a single drug candidate, vopimetostat, while the company burns cash at a rate exceeding revenues and carries a high short interest of 23%. Positive price momentum and strong analyst upside of 23% offer a counter-narrative, but the quality floor failure and binary pipeline risk make this a speculative holding.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Cash Burn Quality Floor→Stable
- High Short Interest Pressure↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Mar 5, 2026
Tango Therapeutics, Inc. (TNGX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $22.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum.
Tango Therapeutics is a clinical-stage precision oncology company developing MTAP-deletion-selective PRMT5 inhibitors with no approved products and no revenue from product sales. Lead asset vopimetostat (TNG462) is in Phase 1/2 trials with a planned 2L pancreatic pivotal trial... Read more
Sell if holding. Engine safety override at $22.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, news boost analyst 0.50, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 5d<=7d. Suitability: speculative.
About Tango Therapeutics, Inc.
About Tango Therapeutics, Inc.
Vopimetostat, Tango Therapeutics' lead MTAP-deletion-selective PRMT5 inhibitor, achieved a 27% objective response rate and 6.4-month median progression-free survival across all MTAP-deleted tumor types at a September 2025 data cut; in second-line pancreatic cancer specifically, mPFS reached 7.2 months. Tango raised $225.0 million in gross proceeds in October 2025 through an underwritten offering and concurrent private placement, and carried an accumulated deficit of $603.2 million at December 31, 2025. The company also advances TNG456, a brain-penetrant PRMT5 inhibitor in Phase 1/2 dose escalation for glioblastoma (GBM).
Tango generates no product revenue and funds operations through collaboration agreements and equity raises. All drug substance manufacturing is outsourced to a single CDMO; drug product manufacturing is split between two CDMOs, one operating outside the U.S. Active clinical collaborations include Revolution Medicines — supplying daraxonrasib and zoldonrasib for a vopimetostat combination trial in MTAP-deleted/RAS-mutant pancreatic and lung cancer, with 30 patients enrolled by December 24, 2025 — and Eli Lilly, which supplies abemaciclib (Verzenio) for TNG456 in GBM. A third program, TNG260 (a CoREST inhibitor), showed a 29-week mPFS in five patients with STK11-mutant/KRAS-wild-type NSCLC in early data, more than double the historical standard of care. The company targets a 2L pancreatic pivotal trial initiation in 2026 across an estimated 60,000 annual addressable U.S. patients for vopimetostat's indications.
Show full overview
The enterprise value of Tango rests on a single pivotal readout: vopimetostat in second-line MTAP-deleted pancreatic cancer. Two prior programs — TNG348 discontinued in May 2024 due to liver toxicity and TNG908 discontinued in November 2024 due to insufficient CNS exposure — illustrate the binary nature of the pipeline. No NDA or MAA has been submitted for any asset. In April 2026, CFO Daniella Beckman departed and was immediately succeeded by Matthew Gall (formerly of Kalaris Therapeutics and iTeos Therapeutics), effective April 15, 2026; this transition did not alter disclosed clinical timelines.
See also: Healthcare · Biotechnology
From Tango Therapeutics, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated 2026-10-29Recent Developments — Tango Therapeutics, Inc.
Latest news
- NEWS HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target — benzinga Oct 29, 2026 positive
- NEWS Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings — benzinga Oct 23, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Oct 23, 2026 neutral
- NEWS Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? — benzinga Oct 23, 2026 negative
- NEWS 12 Health Care Stocks Moving In Friday's Pre-Market Session — benzinga Oct 23, 2026 neutral
Generated 2026-10-29T12:43:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinevopimetostat10-K Item 1: 'We are currently focused on clinical development of two MTAP-deleted selective PRMT5 inhibitors: vopimetostat (TNG462)'
- HIGHSupplierone drug substance manufacturer10-K Item 1: 'all manufacturing of the drug substance for our product candidates to be used in our clinical trials is conducted by one manufacturer'
Material Events(8-K, last 90d)
- 2026-05-13Item 5.02LOWLead Independent Director Alexis Borisy resigned from the Board and as Chairperson of the Compensation Committee, effective May 12, 2026. No reason cited; no successor named as Lead Independent Director.SEC filing →
- 2026-05-08Item 5.02LOWSeparation Agreement with former CFO Daniella Beckman entered May 7, 2026: 12 months severance at base salary, COBRA reimbursement up to 12 months, accelerated vesting equivalent to 24 additional months. Administrative follow-up to April 15, 2026 departure; successor already in place.SEC filing →
- 2026-04-15Item 5.02MEDIUMCFO Daniella Beckman terminated effective April 15, 2026; Matthew Gall (age 49, former CFO of Kalaris Therapeutics and iTeos Therapeutics) appointed CFO effective April 15, 2026. Clean same-day handoff.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -229.9%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $22.23: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 27%; Below-average business quality; Negative price momentum. Chart setup: RSI 49 mid-range, Bollinger mid-band. Prior stop was $20.67. Score 5.3/10, moderate confidence.
Analyst target: $40.97 (+84.3% upside). Prior stop was $20.67. Stop-loss: $20.67.
Concentration risk — Pipeline: vopimetostat; Concentration risk — Supplier: one drug substance manufacturer; Quality below floor (2.4 < 4.0).
Tango Therapeutics, Inc. trades at a P/E of N/A (forward -13.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts cover TNGX with a consensus score of 4.3/5. Average price target: $47.
What does Tango Therapeutics, Inc. do?Tango Therapeutics is a clinical-stage precision oncology company developing MTAP-deletion-selective PRMT5 inhibitors...
Tango Therapeutics is a clinical-stage precision oncology company developing MTAP-deletion-selective PRMT5 inhibitors with no approved products and no revenue from product sales. Lead asset vopimetostat (TNG462) is in Phase 1/2 trials with a planned 2L pancreatic pivotal trial in 2026; TNG456 targets GBM. All drug manufacturing is outsourced to CDMOs, with a single CDMO handling all drug substance production.